Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28, Inc. (NYSE: FNA) is a medical device company based in Englewood, Colorado and exclusively focused on the foot and ankle orthopedic market. This news page aggregates coverage related to the company’s specialized implants, instrumentation and digital tools for foot and ankle surgery, as well as key corporate and regulatory developments.
Readers can find updates on Paragon 28’s participation in major professional meetings such as the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference and the American Academy of Orthopaedic Surgeons (AAOS) Annual Conference. News from these events often highlights recently launched products, including systems for total ankle replacement, fibula fracture stabilization, syndesmotic repair, minimally invasive bunion correction and single-use power systems for foot and ankle procedures.
Coverage also includes announcements about Paragon 28’s digital initiatives, such as the SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠, a platform described as integrating AI, data analytics and 3D modeling to streamline surgical planning and execution. Corporate news items may address preliminary revenue updates, conference presentations, board appointments and legal or shareholder-related matters.
In addition, this page features transaction-related news, including the definitive agreement for Zimmer Biomet Holdings, Inc. to acquire Paragon 28 and subsequent regulatory milestones like the expiration of the Hart-Scott-Rodino Act waiting period. By reviewing these articles, investors and observers can follow how Paragon 28’s product launches, strategic initiatives and proposed corporate transactions shape its role in the foot and ankle orthopedic segment over time.
Paragon 28, Inc. (NYSE: FNA) announced it will release its Q1 2022 financial results after market close on May 9, 2022. A conference call will follow at 4:30 p.m. ET, and investors can access it by calling (844-200-6205) within the U.S. or (646-904-5544) internationally, using conference ID: 990038. CEO Albert DaCosta and CFO Steve Deitsch will also present at the Bank of America Healthcare Conference in Las Vegas on May 10, at 2:00 p.m. PT. Live webcasts will be available on the company’s website.
Paragon 28, Inc. (NYSE: FNA) has appointed Meghan Scanlon to its Board of Directors, enhancing its leadership team. With over 20 years in the medical device sector, Scanlon currently serves as senior vice president at Boston Scientific Corporation. She will also contribute to the Compensation and Quality, Technology and Regulatory Committees. Paragon 28 aims to improve outcomes for foot and ankle patients, focusing on innovative orthopedic solutions and procedural approaches.
Paragon 28, Inc. (NYSE: FNA), a premier medical device company focusing on foot and ankle orthopedics, announced presentations by CEO Albert DaCosta and CFO Steve Deitsch at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022, and the Needham Healthcare Conference on April 11, 2022. Both events will be webcast live, with the Canaccord chat at 12:30pm ET and the Needham chat at 11:00am ET. Archived recordings will be available on the company’s investor relations website.
Paragon 28 (NYSE: FNA) reported Q4 2021 net revenue of $42.8 million, a 22% increase year-over-year, and total revenue of $147.5 million for 2021, reflecting 33% growth. The gross margin improved to 81.7% from 72.3% in the prior year, attributed to higher margin product sales. However, operating expenses surged to $40.0 million, leading to a net loss of $6.2 million. The company expects net revenue for 2022 to be between $167.0 million and $171.0 million, indicating growth of 13% to 16%, despite potential COVID-19 challenges.
Paragon 28, Inc. (NYSE: FNA), a medical device leader in the foot and ankle orthopedic market, will announce its Q4 and full year 2021 financial results on March 8, 2022, after market close. A conference call will follow at 4:30 p.m. ET, accessible via phone or through a webcast on the company’s website. Investors can dial (844-200-6205) domestically or (929-526-1599) internationally using conference ID: 902702. The audio will be archived for 90 days post-event.
Paragon 28, Inc. (NYSE: FNA) has announced the acquisition of Disior Oy, a software company specializing in 3D analytics for foot and ankle surgery. The $18 million upfront payment, with potential future payments of up to $8 million, aims to enhance Paragon 28's SMART 28™ ecosystem. This integration will improve pre-operative planning and surgical outcomes for foot and ankle surgeons, aligning with Paragon 28's mission to modernize surgery and enhance patient care.
Paragon 28, Inc. (NYSE: FNA) announced its preliminary unaudited revenue for Q4 and the full year ended December 31, 2021. Q4 revenue is projected between $42.3 million and $42.7 million, marking a growth of approximately 20.7% to 21.8% year-over-year. For the entire year, expected revenue is between $147.0 million and $147.4 million, reflecting a growth of 32.4% to 32.8% compared to 2020. The company attributes this growth to its innovative foot and ankle portfolio and recent IPO, which has strengthened its financial position.
Paragon 28, Inc. (NYSE: FNA) announced FDA 501(k) marketing clearance for its R3ACT™ Stabilization System, set for commercial launch in early 2022. This product enhances Paragon 28's existing portfolio aimed at ankle fractures and soft tissue stabilization. CEO Albert DaCosta highlighted the product's innovative design, which meets complex needs in syndesmotic stabilization and adapts to healing phases of soft tissues. This new addition complements current offerings, including the Gorilla® and Mini-Monster® systems, strengthening the company's position in the orthopedic market.
Paragon 28, Inc. (NYSE: FNA), a key player in the foot and ankle orthopedic market, announced a virtual presentation at the 24th Annual Needham Growth Conference on January 10, 2022. The event, featuring Chairman and CEO Albert DaCosta and CFO Steve Deitsch, will be webcast live at 2:45 PM ET. The presentation aims to showcase the company's commitment to innovative orthopedic solutions addressing various foot and ankle conditions. Investors can access the webcast and archived recording on the company's investor relations website.
Paragon 28, Inc. (NYSE: FNA) has received FDA supplemental approval for its Patient Specific Talus Spacer, allowing it to be manufactured in titanium alloy with a titanium nitride coating. Initially approved on February 17, 2021, this implant is the only patient-specific total talus replacement authorized in the U.S., providing an alternative to traditional treatments for avascular necrosis of the ankle joint. CEO Albert DaCosta highlighted the expanded material options, which enhance the company’s Precision Ankle Solutions portfolio, including other innovative orthopedic products.